Nabriva Therapeutics AG (NBRV)
(Delayed Data from NSDQ)
$2.16 USD
+0.01 (0.47%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.16 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.16 USD
+0.01 (0.47%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.16 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Rising P/E: An Overlooked Way to Pick 5 Winning Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
CRISPR Therapeutics (CRSP) Q1 Earnings Miss, Revenues Rise Y/Y
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) earnings and revenues miss estimates in the first quarter of 2021. Focus on pipeline development.
Gilead (GILD) Gets FDA Nod for Trodelvy in Urothelial Cancer
by Zacks Equity Research
The FDA grants accelerated approval to Gilead's (GILD) Trodelvy for treating adult patients with locally-advanced or metastatic urothelial cancer.
vTv Therapeutics (VTVT) Gets Breakthrough Tag for Diabetes Drug
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to vTv Therapeutics' (VTVT) TTP399 as an adjunctive therapy to insulin for treating type I diabetes. Shares rise.
Rising P/E: An Overlooked Strategy to Pick Winning Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Seagen's (SGEN) Tisotumab Vedotin BLA Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Seagen (SGEN) and Genmab's BLA for tisotumab vedotin under a priority review to treat recurrent/metastatic cervical cancer. A verdict is pending on Oct 10, 2021.
Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for IPF
by Zacks Equity Research
The FDA grants orphan drug designation to Syndax's (SNDX) axatilimab for the treatment of patients with idiopathic pulmonary fibrosis. Shares up.
Alkermes (ALKS) Inks Deal With Merck for Ovarian Cancer Study
by Zacks Equity Research
Alkermes (ALKS) signs a clinical trial collaboration and supply agreement with Merck to evaluate nemvaleukin alfa in combination with Keytruda for treating platinum-resistant ovarian cancer.
ACADIA (ACAD) Gets CRL From FDA for Nuplazid sNDA, Shares Down
by Zacks Equity Research
The FDA issues a Complete Response Letter to ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock falls.
5 Best Stocks With Rising P/E to Buy for Solid Returns
by Sanghamitra Saha
Forget undervalued stocks, play these top-ranked stocks with rising P/E.
Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for GVHD
by Zacks Equity Research
The FDA bestows an orphan drug designation on Syndax's (SNDX) axatilimab for the treatment of patients with chronic graft versus host disease. Shares up.
Amgen (AMGN) to Boost Inflammation Pipeline With Rodeo Buyout
by Zacks Equity Research
Amgen (AMGN) inks an agreement to acquire privately held company, Rodeo Therapeutics Corporation, to boost its inflammation portfolio.
Incyte (INCY) Gets EU Nod for Cholangiocarcinoma Drug Pemazyre
by Zacks Equity Research
The European Commission approves Incyte's (INCY) Pemazyre (pemigatinib) for the treatment of locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.
Myovant's (MYOV) Data on Relugolix for Uterine Fibroids Positive
by Zacks Equity Research
Myovant (MYOV) and partner Pfizer report positive data from the phase III LIBERTY study evaluating relugolix combination therapy for treating women with uterine fibroids.
Bristol Myers' (BMY) NDA for Mavacamten Accepted by FDA
by Zacks Equity Research
The FDA accepts Bristol Myers' (BMY) new drug application for mavacamten for treating patients with symptomatic obstructive hypertrophic cardiomyopathy.
Implied Volatility Surging for Nabriva (NBRV) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.
ACADIA (ACAD) Falls as FDA Finds Deficiencies in Nuplazid sNDA
by Zacks Equity Research
The FDA identifies deficiencies in ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock sinks.
Nabriva Therapeutics (NBRV) Is in Oversold Territory: What's Next?
by Zacks Equity Research
Nabriva Therapeutics (NBRV) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Cara Therapeutics' (CARA) Korsuva NDA Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Cara Therapeutics (CARA) and Vifor Pharma's NDA for Korsuva injection under a priority review to treat moderate-to-severe pruritus in hemodialysis patients. Shares rise.
Blueprint Medicines (BPMC) Gets EMA Validation for Ayvakyt in SM
by Zacks Equity Research
The EMA validates Blueprint Medicines' (BPMC) Type II variation marketing authorization application for Ayvakyt to treat advanced systemic mastocytosis.
Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss in the fourth quarter of 2020. The company is making good progress with the development of its lead pipeline candidate, KSI-301.
Axsome's (AXSM) Q4 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Axsome (AXSM) reports wider-than-expected loss in the fourth quarter of 2020. The company files an NDA for AXS-05 to treat major depressive disorder.
Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus
by Zacks Equity Research
Apellis' (APLS) bottom line grows year over year in the fourth quarter of 2020 while revenues beat estimates. Main focus of the company is on lead pipeline candidate, pegcetacoplan.
Agios' (AGIO) Q4 Loss In Line, Revenues Surpass Estimates
by Zacks Equity Research
Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year. Shares down.
Editas (EDIT) Misses on Q4 Earnings, Beats on Revenues
by Zacks Equity Research
Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.